Parathyroid hyperplasia

Summary

Parathyroid hyperplasia (MONDO:0006354) is a disease and 5 clinical trials. Top therapeutic interventions include tramadol and (r,r)-tramadol. A subtype of parathyroid gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	parathyroid hyperplasia
Mondo ID	MONDO:0006354
EFO	EFO:1000457
NCIT	C3989
SNOMED CT	9092004
UMLS	C0271844
MedGen	75767
Anatomy (UBERON)	UBERON:0001132
Is cancer (heuristic)	no

Also known as: hyperplasia of parathyroid · hyperplasia of the parathyroid · parathyroid gland hyperplasia · parathyroid hyperplasia · parathyroid hyperplasia (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of parathyroid gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › parathyroid gland disorder › parathyroid hyperplasia

Related subtypes (3): hypoparathyroidism, hyperparathyroidism, tumor of parathyroid gland

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03469310	PHASE4	COMPLETED	Minimizing Narcotic Analgesics After Endocrine Surgery
NCT03027557	PHASE3	COMPLETED	Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
NCT01421407	Not specified	WITHDRAWN	Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism
NCT02636075	Not specified	UNKNOWN	Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases
NCT04299425	Not specified	COMPLETED	Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRAMADOL	4	1
CHEMBL4059722	0	1
(R,R)-TRAMADOL	0	1